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OBJECTIVE — A1C is an optional method for diagnosing diabetes and also for detecting
individualsatincreasedriskofthedisease.However,howA1Ccompareswithfasting(FPG)and
2-h plasma glucose for detecting at-risk individuals is not well known.
RESEARCH DESIGN AND METHODS — A 2-h glucose tolerance test, frequently
sampled intravenous glucose tolerance test, and A1C were obtained at the follow-up examina-
tion in 855 participants in the Insulin Resistance Atherosclerosis Study (IRAS). For this report,
385 individuals were at increased risk of diabetes as deﬁned by A1C between 5.7 and 6.4%,
impaired glucose tolerance (IGT), and/or impaired fasting glucose (IFG).
RESULTS — IFG and IGT identiﬁed 69.1 and 59.5% of all individuals at increased risk of
diabetes, respectively. A1C 5.7–6.4% detected 23.6% of all at-risk individuals, although more
AfricanAmericans(31.4%)andHispanics(35.2%)thannon-Hispanicwhites(9.9%).Relativeto
A1C,FPGwasmorestronglyrelatedtofastinginsulin(r0.38vs.0.26;P0.01),acuteinsulin
response (r  – 0.20 vs. – 0.09; P  0.01), and waist circumference (r  0.43 vs. 0.25; P 
0.001)bytheSpearmancorrelationtest.Similarly,2-hplasmaglucosewasmorestronglyrelated
to Si (r  – 0.40 vs. – 0.27; P  0.01) and triglycerides (r  0.30 vs. 0.08; P  0.001).
CONCLUSIONS — A1C5.7–6.4%islesssensitivefordetectingat-riskindividualsthanIFG
andIGT,particularlyamongnon-Hispanicwhites.SingledeterminationsofFPGand2-hplasma
glucose seem to be more precise correlates of insulin resistance and secretion than A1C and, in
general, better for other metabolic disorders.
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A
1ChasbeenproposedbytheAmer-
ican Diabetes Association (ADA) as
an optional assay for diagnosing di-
abetes and also for detecting individuals
at increased risk of the disease (1). A1C
has been shown to predict future onset of
diabetes (2–4) and is better than fasting
plasma glucose (FPG) for predicting
microvascular complications (1). A1C
may be superior to FPG in predicting
mortality and cardiovascular risk in non-
diabeticindividuals(5)butinferiorto2-h
glucose concentration (2-h plasma glu-
cose) in most studies (6–8), albeit not all
(9). The A1C assay has advantages over
the measurement of plasma glucose in-
cluding convenience (not requiring fast-
ing samples) and superior technical
attributes (1). Conversely, the number of
individuals diagnosed with diabetes by
the 6.5% A1C threshold is signiﬁcantly
smaller than the number of those diag-
nosedbythe2003AmericanDiabetesAs-
sociation (ADA) criteria (10–13). A1C,
FPG, and 2-h plasma glucose assess dif-
ferent aspects of glucose metabolism (1),
but differences in the relation of these three
glycemic measures to insulin resistance, in-
sulin secretion, and other metabolic abnor-
malities have not been described.
A1C between 5.7 and 6.4% (A1C
5.7–6.4%) is now considered a category
of increased risk for diabetes in addition
to impaired fasting glucose (IFG) and im-
paired glucose tolerance (IGT) (1). How-
ever,studiesthatcompareA1C5.7–6.4%
with IFG and IGT are lacking. Therefore,
our aim was twofold: 1) to analyze A1C,
FPG, and 2-h plasma glucose for their
ability to identify individuals at increased
risk of diabetes; and 2) to examine the
relation of these glycemic measures to
other metabolic abnormalities, particu-
larly measured insulin resistance and se-
cretion in nondiabetic subjects.
RESEARCH DESIGN AND
METHODS— The Insulin Resistance
Atherosclerosis Study (IRAS) is an epide-
miologicstudyoftherelationshipsamong
insulin resistance, cardiovascular disease,
and its known risk factors (sociodemo-
graphic variables, family history, blood
pressure, dyslipidemia, obesity, and
chronic inﬂammation) in three ethnic
groups (non-Hispanic whites, African
Americans, and Hispanics) and different
states of glucose tolerance (normal glu-
cose tolerance, IGT, and type 2 diabetes).
The design and methods of this study
have been described previously (14). In
brief, the study was conducted at four
clinical centers: Oakland and Los Ange-
les, California, San Antonio, Texas, and
San Luis Valley, Colorado. A total of
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October 1992 and April 1994 (mean age
54.6 years, range 40–69 years; 56%
women). After an average of 5.2 years
(range 4.5–6.6 years), follow-up exami-
nations were conducted using the same
baseline protocol. The response rate was
81%, and those who attended the fol-
low-up examination were similar to those
who did not in terms of ethnicity, sex,
baselineglucosetolerancestatus,andBMI
(all comparisons, P  0.32). The IRAS
protocol was approved by local institu-
tional review committees, and all partici-
pantsprovidedwritteninformedconsent.
Subjects described in this study have
been part of many previous reports.
Among 1,065 participants who were free
of diabetes (2003 ADA criteria), 22 died
during the follow-up period and 890
(85.3%) returned to the follow-up exam-
ination. We excluded 13 participants be-
cause of treatment with glucose-lowering
agents and 22 others because of missing
information. This report is limited to 855
of 1,030 eligible participants (83.0%)
who attended the follow-up examination,
because A1C was only measured at this
time point (mean age 59.8 years; range
44–75 years).
Clinical measurements and
procedures
Baseline and follow-up examinations re-
quired two visits. During the ﬁrst visit, a
75-g OGTT was administered to assess
glucose tolerance status. During the sec-
ond visit a week later, insulin sensitivity
and ﬁrst-phase insulin secretion were di-
rectly measured by the frequently sam-
pled intravenous glucose tolerance test
with two modiﬁcations to the original
protocol. First, an injection of regular in-
sulin was used to ensure adequate plasma
insulin levels for the accurate computa-
tion of insulin sensitivity across a broad
range of glucose tolerance (14). Second,
the reduced sampling protocol (12 sam-
ples) was used because of the large num-
ber of subjects. Insulin sensitivity,
expressed as the insulin sensitivity index
(Si), was calculated using mathematical
modeling methods (MINMOD version
3.0, 1994, Los Angeles, CA; courtesy of
RichardBergman,PhD).First-phaseinsu-
lin secretion, expressed as acute insulin
response (AIR), was computed as the
mean of 2- and 4-min insulin concentra-
tions after glucose administration.
Anthropometric variables were mea-
sured by trained personnel. Plasma glucose
and serum lipid, lipoprotein, and insulin
concentrations were determined as de-
scribedpreviously(14).A1Cwasmeasured
by an automated microparticle immunoas-
say using whole blood (Medlantic Research
Institute, Washington, DC) (15).
Diabeteswasdeﬁnedashavingdiabe-
tes according to the 2003 ADA criteria
(FPG126mg/dland/or2-hplasmaglu-
cose 200 mg/dl) or A1C 6.5% (1). In-
dividuals taking glucose-lowering
medications were excluded. In the ab-
senceofdiabetes,IFGwasdeﬁnedasFPG
100–125 mg/dl and IGT as 2-h plasma
glucose140–199mg/dl.Intheabsenceof
diabetes, participants with A1C 5.7–
6.4%and/orIFGand/orIGTwereconsid-
ered at increased risk (1). Metabolic
syndrome and metabolic disorders were
deﬁned according to the “harmonizing
the metabolic syndrome” criteria (16).
Statistical analyses
Analyses were performed using SAS
statisticalsoftware(version9.1;SASInsti-
tute, Cary, NC). Differences in continu-
ous and dichotomous variables between
groups were analyzed by ANCOVA and
logistic regression analysis, respectively.
Spearman correlation coefﬁcients were
used to examine the relationship between
glycemic measures as well as with other
metabolic variables. Linear regression
analysis was also used to assess the inde-
pendent relation of glycemic measures to
Si and AIR. The strength of these associa-
tions was determined by calculating the
R
2 statistics. In these analyses, log-
transformedvaluesofallcontinuousvari-
ableswereusedtominimizetheinﬂuence
ofextremeobservations.Wealsousedthe
log transformation of (Si  1) given that
someparticipantshadSi0andthelogit
transformationofFraminghamriskscore.
We used the area under the receiver op-
erating characteristic curve (AUC) to as-
sess the ability to detect subjects with Si
(or AIR) in the lower quartile (or 2 met-
abolic abnormalities with hyperglycemia
excluded).
RESULTS— Characteristics of partici-
pants by A1C categories are presented in
Table 1. Most metabolic variables includ-
ing Si and AIR worsened with increasing
A1C.
Ability of A1C >6.5% to detect of
individuals with diabetes
A total of 136 of 855 (15.9%) individuals
had diabetes. A1C 6.5% identiﬁed
32.3% of all individuals with diabetes.
FPG 126 mg/dl and 2-h plasma glucose
200 mg/dl detected a larger percentage
(44.8and86.8%,respectively).Thecom-
bination of A1C 6.5% and/or FPG
126 mg/dl detected 52.2% of diabetic
subjects and the combination of IFG
and/or IGT detected 97.1%.
Relation of glycemic measures to
metabolic variables in nondiabetic
individuals
FPG was more strongly correlated with
A1C than was 2-h plasma glucose (r 
0.39 vs. 0.25; P  0.001) in nondiabetic
subjects(Table2).Thecorrelationsof2-h
plasma glucose with Si, systolic blood
pressure, and triglycerides were stronger
than the corresponding correlations of
A1C. FGP had also more robust correla-
tions with fasting insulin, AIR, obesity,
andsystolicbloodpressurethandidA1C.
Relationship among glycemic
measures, Si, and AIR in nondiabetic
individuals
In linear regression analysis, A1C ex-
plained 7.4% of the Si variance and FPG
and 2-h plasma glucose accounted for
10.3 and 13.8%, respectively. Si ac-
counted for 11.3% of the AIR variance,
but addition of A1C to the model in-
creased the variance explained by 4.2%,
addition of FPG by 10.2%, and addition
of 2-h plasma glucose by 8.7%.
A multivariate linear regression
model was ﬁtted with Si as the dependent
variable and age, sex, race/ethnicity, re-
searchcenter,andallthreeglycemicmea-
suresasindependentvariables.Expressed
per 1 SD, regression coefﬁcients demon-
stratedthatA1C(0.040.02,P
0.038), FPG ( 0.08  0.02, P 
0.001), and 2-h plasma glucose (
0.140.02,P0.001)wereindepen-
dently related to Si. Similarly, we ﬁtted a
second model with AIR as the dependent
variable and demographic variables, Si,
and all three glycemic measures as inde-
pendent variables. A1C ( 0.11 
0.03; P  0.001), FPG ( 0.16 
0.03,P0.001),and2-hplasmaglucose
(0.150.03,P0.001)werealso
independently associated with AIR.
In separate models, there was strong
effect modiﬁcation of race/ethnicity on
therelationofeachglycemicmeasuretoSi
(Fig.1).InAfricanAmericans,2-hplasma
glucose was weakly related and A1C and
FPG were not related to Si. Sex had an
interaction effect on the relationship be-
tween A1C and Si and between 2-h
plasma glucose and AIR (stronger in
women for both). Obesity had a similar
Lorenzo and Associates
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cose measure to AIR (stronger in obese
individuals).
Identiﬁcation of at-risk individuals
Atotalof385of719(53.5%)nondiabetic
individuals were at increased risk of dia-
betes (Table 3). The proportion of these
individuals identiﬁed by A1C 5.7–6.4%,
IFG, and IGT was 23.6, 69.1, and 59.5%,
respectively. The combination of IFG
and/or IGT detected 95.8% and the com-
binationofIFGand/orA1C5.7–6.4%de-
tected 75.6%. At-risk individuals were
more frequently identiﬁed by IFG if they
were men, African Americans, or non-
Hispanic whites, and if they were young,
overweight, or obese. At-risk individuals
were more commonly detected by IGT if
they were women or Mexican Americans.
A1C 5.7–6.4% detected few non-
Hispanic whites at increased risk of dia-
betes and was more effective with
worsening BMI.
We used AUCs to assess the ability
to detect individuals in the lower quar-
tile of Si (supplementary Figure, avail-
able in an online appendix at http://
care.diabetesjournals.org/cgi/content/full/
dc10-0679/DC1). The AUC of A1C was
smaller than that of 2-h plasma glucose
(0.620 vs. 0.682; P  0.048) but was not
statistically different from that of FPG
(0.654; P  0.239). The three glycemic
measures performed poorly in detecting
individuals in the lower quartile of AIR,
althoughFPG(0.583;P0.029)and2-h
plasma glucose (0.590; P  0.027) dis-
playedlargerAUCsthandidA1C(0.520).
Finally, the AUC of A1C for detecting
individuals with 2 metabolic abnor-
malities (excluded hyperglycemia) was
smaller than that of 2-h plasma glucose
(0.598 vs. 0.702; P  0.001) but was not
signiﬁcantly different from the AUC of
FPG (0.643; P  0.064).
CONCLUSIONS — A1C 5.7– 6.4%
identiﬁes a much smaller proportion of
individuals at increased risk of diabetes
than do IFG and IGT, particularly among
Table2—Spearmancorrelationcoefﬁcientsfortherelationshipbetweenglycemicmeasuresas
well as with other metabolic variables in nondiabetic participants
A1C Fasting glucose 2-h glucose
Fasting glucose 0.39 — —
2-h glucose 0.25 0.34 —
Fasting insulin 0.26 0.38* 0.28
Si 0.27 0.34 0.40*
AIR 0.09 0.20* 0.18
BMI 0.20 0.28† 0.24
Waist circumference 0.25 0.43‡ 0.22
Systolic blood pressure 0.10 0.21* 0.29‡
Diastolic blood pressure 0.08 0.15 0.10
Total cholesterol 0.07 0.03 0.07
Triglycerides 0.08 0.14 0.30‡
HDL cholesterol 0.13 0.21 0.16
P value for test of difference in the correlation of each plasma glucose measure with individual metabolic
variables relative to the correlation of A1C with the same metabolic variable. *P  0.01; †P  0.05; ‡P 
0.001.
Table 1—Characteristics by categories of A1C adjusted for age, sex, race/ethnicity, and research center
1: A1C 5.7% 2: A1C 5.7–6.4% 3: A1C 6.5%
P value
1 vs. 2 1 vs. 3 2 vs. 3
n 673 138 44 — — —
Age (years)* 59.6  0.3 60.7  1.3 59.6  1.3 0.177 0.984 0.418
Female (%)* 57.2 (53.4–60.9) 55.8 (47.4–63.9) 61.4 (46.4–74.4) 0.760 0.589 0.516
Ethnicity (%)* 0.001 0.006 0.544
African Americans 23.6 (20.6–27.0) 30.4 (23.3–38.6) 38.7 (25.6–53.6)
Hispanics 31.5 (28.1–35.1) 45.7 (37.5–54.0) 36.4 (23.6–51.4)
Non-Hispanic whites 44.9 (41.2–48.7) 23.9 (17.5–31.7) 25.0 (14.4–39.7)
BMI (kg/m
2) 28.1  0.2 32.5  0.5 32.2  0.8 0.001 0.001 0.600
Waist circumference (cm) 90.4  0.4 100.3  1.5 100.5  1.7 0.001 0.001 0.879
Systolic blood pressure (mmHg) 125.8  0.7 127.9  1.5 130.9  2.6 0.207 0.059 0.459
Diastolic blood pressure (mmHg) 77.5  0.3 78.4  0.8 79.7  1.4 0.295 0.139 0.661
Antihypertensive medications (%) 18.9 (15.7–22.6) 31.2 (23.6–39.9) 17.6 (9.2–30.9) 0.002 0.793 0.085
Triglycerides (mg/dl)† 109.1  2.2 125.3  5.5 142.2  11.2 0.018 0.001 0.128
HDL cholesterol (mg/dl) 50.7  0.5 45.6  1.2 43.4  2.1 0.001 0.001 0.402
Total cholesterol (mg/dl) 209.0  1.4 208.1  3.1 202.2  5.4 0.786 0.214 0.316
Treatment for high cholesterol (%) 6.1 (4.0–9.3) 14.2 (8.3–23.3) 8.5 (2.6–24.5) 0.763 0.608 0.534
Fasting glucose (mg/dl) 95.8  0.6 110.8  1.4 160.5  2.5 0.001 0.001 0.001
2-h glucose (mg/dl) 128.9  1.8 171.8  4.0 272.2  7.1 0.001 0.001 0.001
Metabolic syndrome (%) 38.9 (34.7–43.2) 73.7 (65.2–80.7) 82.2 (67.8–91.0) 0.001 0.001 0.247
Fasting insulin (U/ml)† 14.3  0.3 22.6  1.2 21.8  1.8 0.001 0.001 0.655
Si (	 10
4 min
1   U
1   ml
1)† 1.27  0.05 0.67  0.07 0.46  0.11 0.001 0.001 0.156
AIR (U/ml)† 68.8  2.0 49.6  3.4 27.1  3.3 0.041 0.001 0.001
Data are mean  SEM or rates with 95% CI. *Unadjusted results. †Log-transformed variables. These variables were then back-transformed to their units for
presentation in the table.
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dependent variable, age, sex, race/ethnicity, and center were included as covariates. In models with AIR as the dependent variable, age, sex,
race/ethnicity, research center, and Si were included as covariates. Continuous variables were log transformed to meet the speciﬁcations of the test.
Estimates are expressed per 1 SD unit change.
Lorenzo and Associates
care.diabetesjournals.org DIABETES CARE, VOLUME 33, NUMBER 9, SEPTEMBER 2010 2107non-Hispanic whites and lean individu-
als. A1C is a less precise correlate of insu-
lin resistance and insulin secretion in
studies of metabolism than single deter-
minations of FPG and 2-h plasma glucose
and, in general, is worse for other meta-
bolic disorders.
In participants in the 2003–2006 Na-
tional Health and Nutrition Examination
Survey (NHANES), A1C between 6.0 and
6.4% missed 90% of the individuals at
increased risk of diabetes (11). Our re-
sults suggest that the newly proposed cat-
egory, A1C 5.7–6.4%, still misses three-
quarters of them. Similarly, in a recent
study from Qingdao, China, A1C was un-
able to distinguish individuals with IFG
and/or IGT from those with normal glu-
cose tolerance (17). Conversely, in a
study from Chennai, India, A1C 5.7%
detected two-thirds of individuals with
IFG and/or IGT (18). The performance of
A1C 5.7–6.4% may differ among studies
owing to differences in the target popula-
tion. Ginde et al. (19) have reported that
risk stratiﬁcation improves the ability of
A1C to screen for undiagnosed diabetes.
In our study, A1C 5.7–6.4% performs
poorly among non-Hispanic whites and
lean individuals. The 2010 ADA report
indicated that the risk of diabetes associ-
atedwithA1C5.7–6.4%iscomparableto
that in participants in the Diabetes Pre-
vention Program (DPP) (1). Because DPP
participants in the control arm had an 11%
peryearincidenceofdiabetes(20),itwould
be beneﬁcial to detect individuals at an ear-
lier stage of the disease process so that they
may beneﬁt from lifestyle changes. In clini-
cal and epidemiological settings, a signiﬁ-
cant proportion of individuals even with
A1C 5.5% have either IFG or IGT (21).
Thus,A1C5.7–6.4%maybeinadequateas
the only criterion for detecting individuals
at increased risk of the disease.
Inoue et al. (4) have reported than
both IFG and A1C between 5.5 and 6.4%
are independent predictors of conversion
to diabetes (4). In nondiabetic individu-
als, little of the Si (and AIR) variance is
explainedbyA1C;inthisregard,FPGand
2-h plasma glucose seem to be somewhat
better. FPG correlates better with fasting
insulin and ﬁrst-phase insulin secretion
compared with A1C. Similarly, 2-h
plasma glucose correlates better with di-
rectly measured insulin resistance than
does A1C. Nevertheless, each of the three
glycemic measures is related to both Si
andAIR,independentlyoftheeffectofthe
other two measures. This is probably so
because each glycemic measure reﬂects
unique domains of glucose metabolism.
Furthermore, FPG and 2-h plasma glu-
cose may be superior to A1C in their re-
lationship with metabolic variables other
than insulin resistance and insulin secre-
tion. The preeminence of A1C as a better
indicator of future complications, at least
relative to fasting glucose (1,5), is in agree-
ment with the concept of “metabolic mem-
ory,” which postulates that hyperglycemia
leaves a very early imprint on the progres-
sion to complications (22). However, A1C
isinferiorformetabolicabnormalities(insu-
lin resistance and secretion, obesity, and
triglycerides), which may be more deter-
mined by acute levels of glycemia.
A1C 6.5% identiﬁes one-third of
patients with diabetes. A larger percent-
age is detected by FPG 126 mg/dl and
2-h plasma glucose 200 mg/dl (45 and
87%, respectively). These results are al-
most identical to those derived from
2003–2006 NHANES data (30% of dia-
betic individuals detected by A1C
6.5%, 46% by FPG 126 mg/dl, and
90% by 2-h plasma glucose 200 mg/dl)
(11). In Qingdao, China, the 6.5% A1C
cut point also detects 30% of individuals
withdiabetes(2003ADAcriteria)(17).In
Chennai, India, however, A1C 6.5%
detects 78% of individuals with newly di-
agnosed diabetes (18). Furthermore, the
6.5% A1C threshold seems to be speciﬁc
for detecting undiagnosed diabetes de-
ﬁned by a single measure of FPG (12,23)
and identiﬁes retinopathy better than do
FPG 126 mg/dl (1) and 2-h plasma glu-
cose 200 mg/dl (13). It seems logical to
use A1C 6.5% as a criterion for diagnos-
ing diabetes provided that the plasma glu-
cose criteria stay in use. The 6.5% A1C
thresholdmissesalargepercentageofundi-
agnosed diabetes, and the clinical conse-
quences of A1C screening remain
unknown.Lesssensitivitycouldleadtoun-
dertreatment for cardiovascular disease if
future recommendations integrate the risk
of diabetes as part of the algorithm.
There are practical considerations as
well. Although A1C is convenient, given
that it does not require the fasting state, it
is substantially more expensive to analyze
than plasma glucose tests. Patients are
commonly asked to come in fasting for
other types of tests (e.g., LDL cholesterol
andtriglycerides),andthereislittleadded
effort required if the alternative FPG is
paired with other fasting tests. There is
also the concern of potential racial differ-
ences in the interpretability of A1C. The
DPP and others have reported ethnic dif-
ferences in the way A1C correlates to glu-
cose levels among individuals with IGT,
suggesting the potential for further detec-
tion disparities (24). In this regard, our
results suggest that A1C does not reﬂect
the same domain of glucose metabolism
across ethnic groups. Furthermore, our
study indicates that A1C 5.7–6.4% de-
tects at-risk individuals better as BMI
Table 3—Sensitivity of A1C 5.7– 6.4%, IFG, and IGT for detecting individuals at increased
risk of diabetes by age, sex, race/ethnicity, and BMI categories
Nondiabetic
individuals
At-risk
individuals
A1C 5.7– 6.4%
sensitivity
IFG
sensitivity
IGT
sensitivity
All 719 385 (53.5) 23.6 69.1 59.5
Age categories
44–54 years 237 108 (45.6) 20.4 72.2 47.2
55–64 years 253 146 (57.7) 27.4 67.8 65.1
65–75 years 229 131 (57.2) 22.1 67.9 63.4
Sex
Men 314 182 (58.0) 24.7 81.9 48.3
Women 405 203 (50.1) 22.7 57.6 69.5
Race/ethnicity
African Americans 184 102 (55.4) 31.4 73.5 45.1
Hispanics 240 122 (50.8) 35.2 59.0 71.3
Non-Hispanic
whites
295 161 (54.6) 9.9 73.9 59.6
BMI categories
25 kg/m
2 183 64 (35.0) 10.9 57.8 62.5
25–29.9 kg/m
2 337 186 (55.2) 19.9 72.0 58.1
30 kg/m
2 199 135 (67.8) 34.8 70.4 60.0
Data are n, n (%), or %. Nondiabetic individuals with A1C 5.7–6.4%, IFG, or IGT were considered at
increased risk of diabetes.
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in diabetic patients with chronic kidney
disease (stages 3–4) has been shown to
underestimate actual glucose values (25),
nor is A1C accurate in individuals with
anemia and hemoglobinopathies (1).
Whether this is a concern in detection of
at-risk individuals is unclear.
A signiﬁcant limitation of our study is
the use of single determinations of plasma
glucose values. Nevertheless, single deter-
minations of FPG and 2-h plasma glucose
seemtobemoreprecisecorrelatesofinsulin
resistance and secretion than A1C and, in
general, better for other metabolic
disorders.
In summary, the 6.5 and 5.7% A1C
thresholds have a low sensitivity for de-
tecting individuals with diabetes and at
increased risk for the disease, respec-
tively.A1C5.7–6.4%performspoorlyfor
identifying at-risk individuals among
non-Hispanic whites but is more effective
asBMIincreases.A1Cisalessprecisecor-
relate of insulin resistance and insulin se-
cretioninstudiesofmetabolismthanFPG
and2-hplasmaglucoseand,ingeneral,is
worse for other metabolic disorders. Fur-
ther studies are needed for assessing the
relation of glycemic measures to meta-
bolic abnormalities.
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